Discover the latest on Arbutus Biopharma’s patent litigation strategy and investment risks. Learn if ABUS is a speculative ...

Background Current microbiome-based therapeutics face two prominent issues: the limited clinical efficacy of probiotics and the significant variability in the efficacy of microbiota transplantation ...

New range, power, performance and suspension tech reinforce the position of one of the world's greatest sporting EVs ...

Accurate measurement of time-varying systematic risk exposures is essential for robust financial risk management.

Absci is developing ABS-101, an anti-TL1A antibody with potential in ulcerative colitis, Crohn's disease, and other ...